- Global Pharma News & Resources

World’s leading Biobanks join BC Platforms Global Data Partner Network to Advance Personalized Healthcare Research

Total number of consented patient records in network reaches 3.5 million 

6th April 2020 - Zurich, Switzerland and Boston, US - BC Platforms, a global leader in providing a powerful data and technology platform for personalized healthcare, today announced it has added three new leading biobanks to its Global Data Partner Network,, including Generation Scotland, UK, Bialystok Biobank, Poland, and Biobank Graz Austria.  The platform is a streamlined solution for researchers to efficiently access harmonized data while strictly adhering to global and local data privacy and security regulations.  The platform and its supporting framework enable collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.

The addition of these three new, high quality biobanks brings the network to almost 3.5M consented patient healthcare records from nearly ten countries in North America and Europe.  Bialystok Biobank focuses on clinical samples for cancer and specifically on new biomarkers for early diagnosis as well as personalized therapy of cancer based on genetic-molecular disorders. Biobank Graz is one of the biggest biobanks in the world with 20 million tissue, blood and DNA samples from over 1.2 million patients.  Generation Scotland is a population-based cohort designed to study the genetic and environmental determinants of health.

Dr. Christian Gülly, COO, Biobank Graz, Medical University of Graz, Austria, commented, “We are excited to be collaborating with BC Platforms to securely share our data for the benefit of patients without compromising any privacy issues. We have been impressed by the platform and its ability to analyze, integrate and share data in a secure manner and in line with the European General Data Protection Regulation (GDPR) to support researchers in developing personalized medicines.”

Tero Silvola, CEO of BC Platforms, said, “We are delighted to collaborate with these prestigious biobanks in order to make their high-quality data available to researchers through We believe our rapidly growing network provides a unique and invaluable asset for researchers and industry, given our very strong focus on genetic and clinical data. This will progress the development of personalized healthcare for the benefit of patients, healthcare systems and research.”



Editor Details

  • Company:
    • BC Platforms
  • Name:
    • BC Platforms
Last Updated: 06-Apr-2020